Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | 667 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
15.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 15.05.2025 | 931 | Xetra Newsboard | Das Instrument B8D CH1107979838 R+S GROUP HOLDI CUM.PREF. EQUITY wird cum Kapitalmassnahme gehandelt am 15.05.2025 und ex Kapitalmassnahme am 16.05.2025 The instrument B8D CH1107979838 R+S GROUP HOLDI... ► Artikel lesen | |
MEDESIS PHARMA Aktie jetzt für 0€ handeln | |||||
11.03. | XFRA 76D: AUSSETZUNG/SUSPENSION | 227 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMEDESIS PHARMA SA... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIOGEN | 125,50 | -3,05 % | Erste Patienten bekommen Alzheimer-Mittel Lecanemab der Hersteller Biogen und Eisai | BERLIN (dpa-AFX) - Seit gut einem Monat ist das Alzheimer-Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit der Therapie... ► Artikel lesen | |
ILLUMINA | 79,48 | -4,72 % | ILMN Stock Set to Benefit From the Launch of New BioInsight Division | ||
NANOREPRO | 1,665 | -2,35 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
09.10.2025 / 12:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
BIONXT SOLUTIONS | 0,538 | -0,74 % | BioNxt Solutions' Pharma-Revolution: Neue Wege der Wirkstoffverabreichung von Blockbustern | ||
CYTODYN | 0,214 | +0,94 % | CytoDyn Inc. - 10-Q, Quarterly Report | ||
IMMUNIC | 0,758 | -4,65 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in October | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in October
01.10.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
ADAPTIVE BIOTECHNOLOGIES | 13,110 | -3,28 % | A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts | ||
LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
GENPREX | 1,820 | -100,00 % | Ryan Confer, President and Chief Executive Officer of Genprex, Inc., to Present at Investor Summit Virtual on September 16, 2025 | AUSTIN, TX / ACCESS Newswire / September 10, 2025 / Genprex, Inc.'s President and Chief Executive Officer, Ryan Confer, will present at the Investor Summit Virtual on September 16, 2025, offering investors... ► Artikel lesen | |
AMICUS THERAPEUTICS | 7,300 | +2,10 % | Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates | Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including... ► Artikel lesen | |
CIDARA THERAPEUTICS | 96,50 | +0,52 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention | SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics... ► Artikel lesen | |
PERSONALIS | 7,010 | -5,97 % | Personalis, Inc.: Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing | Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate... ► Artikel lesen | |
VITROLIFE | 12,890 | -0,15 % | VITROLIFE AB: Invitation to Vitrolife Group's presentation of the Q3 2025 interim report | ||
PLURI | 4,660 | -100,00 % | Pluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. | Acquisition of approximately 71% stake in Kokomodo Ltd.Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.'s ability to craft real, controlled, climate-resilient... ► Artikel lesen | |
ADOCIA | 9,710 | -5,91 % | Number of Shares and Voting Rights of ADOCIA as of September 30th, 2025 | Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité... ► Artikel lesen |